Hongrui Meng | Neurodegenerative disease | Excellence in Research Award

Prof. Dr. Hongrui Meng | Neurodegenerative disease | Excellence in Research Award

Prof. Dr. Hongrui Meng,  Institute of Neuroscience, Soochow University, China.

Dr. Hongrui Meng is a highly accomplished neuroscientist whose academic path began with a Ph.D. in Behavioural Neuroscience from Hamamatsu University School of Medicine in Japan. He later conducted postdoctoral research in molecular neurobiology and human genetics at Juntendo University, Tokyo. Currently a professor at the Institute of Neuroscience, Soochow University, Dr. Meng leads a research team dedicated to uncovering the molecular and mitochondrial mechanisms underlying Parkinson’s disease and ALS. His work spans high-impact research projects funded by JSPS, NSFC, and other prestigious bodies. In addition to numerous scientific publications, he has contributed to diagnostic innovation through patented miRNA detection methods. His influence extends beyond academia through translational applications such as wearable technologies for Parkinson’s symptom monitoring.

Profile

Orcid

🎓 Early Academic Pursuits

Dr. Hongrui Meng began his distinguished academic journey in the field of neuroscience by earning his Ph.D. in Behavioural Neuroscience from the prestigious Hamamatsu University School of Medicine in Japan. His early education and training laid a strong foundation in experimental neuroscience, with a focus on the behavioral manifestations of neurodegenerative conditions. These formative years not only sharpened his scientific curiosity but also equipped him with the cross-disciplinary expertise to address complex neurological questions.

🧠 Professional Endeavors

Following his doctoral studies, Dr. Meng advanced his specialization through postdoctoral training in molecular neurobiology and human genetics at Juntendo University in Tokyo. There, he immersed himself in high-level research focusing on the genetic underpinnings of neurological disorders. His competence and dedication soon earned him a faculty appointment as an Assistant Professor in the Department of Research for Neurodegenerative Diseases and Dementia. His professional arc reached a significant milestone in 2020 when he was promoted to Full Professor and moved to the Institute of Neuroscience at Soochow University, where he now leads the Laboratory of Molecular Neurology.

🧬 Contributions and Research Focus

Dr. Meng’s scientific contributions center on the molecular mechanisms of Parkinson’s disease and amyotrophic lateral sclerosis (ALS). His research bridges mitochondrial dysfunction, alpha-synuclein aggregation, and neurodegeneration. He has completed pivotal studies supported by the Japan Society for the Promotion of Science and the Takeda Pharmaceutical Foundation, delving into the role of CHCHD2 gene mutations and mitochondrial pathways. His ongoing projects funded by the National Natural Science Foundation of China (NSFC) explore mitochondrial unfolded protein responses (mtUPR), while another innovative project in Suzhou focuses on wearable technology for monitoring Parkinson’s disease symptoms—demonstrating his commitment to translational and patient-centered neuroscience.

🔬 Innovation and Scientific Output

A notable innovator, Dr. Meng has made strides in molecular diagnostic technologies. His work has led to the development of high-throughput RT-qPCR-based methods for detecting primary and precursor miRNAs, contributing to enhanced genetic analysis of neurodegenerative disorders. He holds a patent granted in South Africa and another under process in China, underscoring his role at the intersection of research and technology. Furthermore, his publications in highly regarded journals like Current Issues in Molecular Biology and Cell Communication and Signaling reflect a consistent record of impactful findings that inform both fundamental neuroscience and clinical approaches.

🏅 Accolades and Recognition

Dr. Meng’s ascent in the academic community has been marked by numerous grants, including multiple from the JSPS and NSFC, attesting to the trust placed in his research vision by top funding bodies. While a formal list of awards may be under-documented, his rapid progression from postdoctoral fellow to professor and research team leader in less than a decade speaks volumes about his recognition among peers and institutional leadership. His leadership in multi-disciplinary and international collaborations is an implicit accolade of his scientific reliability and visionary perspective.

🌍 Impact and Influence

Through his groundbreaking work on mitochondrial mechanisms and neurodegeneration, Dr. Meng is helping to reshape current understanding of Parkinson’s disease pathophysiology. His investigations into alpha-synucleinopathy and microglial disruption have provided fresh insights into cellular degeneration and neuroimmune interactions. Beyond academia, his involvement in developing wearable diagnostic tools highlights his drive to impact patient lives directly. As a consultant on neuroprotective treatments such as PD-018/19, he bridges the academic and pharmaceutical worlds to accelerate therapeutic discovery.

🔮 Legacy and Future Contributions

Looking forward, Dr. Meng is poised to be a leading figure in neurogenetic diagnostics and therapeutic innovation. His laboratory at Soochow University serves as an incubator for future discoveries in neurodegenerative disease mechanisms, and his continued work in mitochondrial research promises to inform emerging therapies. With a growing publication record, international patents, and a robust research pipeline, Dr. Meng’s legacy will be one of bridging basic neuroscience with clinical application—paving the way for novel interventions and a better understanding of brain disorders in the molecular era.

Publication

 

  • Title: Dicer Is Involved in Cytotoxicity and Motor Impairment Induced by TBPH Deficiency
    Authors: Xiang Long, Yijie Wang, Hongrui Meng
    Year: 2025

 

  • Title: Transcriptomic analysis of lipid metabolism genes in Alzheimer’s disease: highlighting pathological outcomes and compartmentalized immune status
    Authors: Sun Y., Zhang Y., Jiang M., Long X., Miao Y., Du H., Zhang T., Meng H., Ma X.
    Year: 2024

 

  • Title: CHCHD2 P14L, found in amyotrophic lateral sclerosis, exhibits cytoplasmic mislocalization and alters Ca2+ homeostasis
    Authors: Aya Ikeda, Hongrui Meng, Daisuke Taniguchi, Muneyo Mio, Manabu Funayama, Kenya Nishioka, Mari Yoshida, Yuanzhe Li, Hiroyo Yoshino, Tsuyoshi Inoshita et al.
    Year: 2024

 

  • Title: TDP-43 mutations-induced defects in miRNA biogenesis and cytotoxicity by differentially obstructing Dicer activity in Drosophila and in vitro
    Authors: Xiang Long, Mengni Jiang, Yongzhen Miao, Huanhuan Du, Ting Zhang, Zhuoya Ma, Jiao Li, Chunfeng Liu, Hongrui Meng
    Year: 2024

 

  • Title: A Simple Technique to Assay Locomotor Activity in Drosophila
    Authors: Long X., Du H., Jiang M., Meng H.
    Year: 2023

 

  • Title: Functional MHCI deficiency induces ADHD-like symptoms with increased dopamine D1 receptor expression
    Authors: Meng H.-R., Suenaga T., Edamura M., Nakahara D., Murakami G., Fukuda A., Ishida Y.
    Year: 2021

 

  • Title: Light-driven activation of mitochondrial proton-motive force improves motor behaviors in a Drosophila model of Parkinson’s disease
    Authors: Imai Y., Hattori N., Inoshita T., Shiba-Fukushima K., Meng H., Hara K.Y., Sawamura N.
    Year: 2019

 

  • Title: Mutations in CHCHD2 cause α-synuclein aggregation
    Authors: Ikeda A., Nishioka K., Takanashi M., Li Y., Mori A., Okuzumi A., Izawa N., Ishikawa K.-I., Funayama M., Imai Y. et al.
    Year: 2019

 

  • Title: Parkinson’s disease-associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling
    Authors: Mori A., Hatano T., Koinuma T., Kubo S.-I., Spratt S., Yamashita C., Okuzumi A., Imai Y., Hattori N., Inoshita T. et al.
    Year: 2019

 

  • Title: Twin CHCH proteins, CHCHD2, and CHCHD10: Key molecules of Parkinson’s disease, amyotrophic lateral sclerosis, and frontotemporal dementia
    Authors: Imai Y., Hattori N., Meng H., Shiba-Fukushima K.
    Year: 2019

 

🧾 Conclusion

Dr. Hongrui Meng’s career reflects a dynamic blend of academic excellence, molecular research innovation, and translational neuroscience. His scientific endeavors have not only enriched the understanding of neurodegenerative diseases but have also paved the way for novel diagnostic and therapeutic strategies. With a growing portfolio of impactful research, patents, and leadership in neurobiology, Dr. Meng stands out as a driving force in the global fight against neurological disorders. His work promises continued contributions to neuroscience with lasting influence on both scientific knowledge and patient care.

 

Rosario Osta | Molecular and Cellular Neuroscience | Best Researcher Award

Prof.Dr. Rosario Osta | Molecular and Cellular Neuroscience | Best Researcher Award

Prof. Dr. Rosario Osta, CIBERNED-Fundación Instituto de Investigación Sanitaria de Aragón-Universidad de Zaragoza,  Spain.

Prof. Rosario Osta Pinzolas is a distinguished geneticist and full professor at the University of Zaragoza, Spain. Her academic roots in veterinary sciences and a Ph.D. in Genetics laid the foundation for a prolific career in biomedical research, particularly in the fields of neuroscience and genetic disorders. With leadership roles in multiple high-profile research consortia such as CIBERNED, TRICALS, and ENCALS, she has established herself as a central figure in neurodegenerative disease research. Her scholarly output includes over 100 indexed publications, multiple national and international research projects, and an h-index exceeding 45.

Profile

Orcid 

Scopus

 

🎓 Early Academic Pursuits

Rosario Osta Pinzolas began her academic journey with a solid foundation in veterinary sciences, graduating as Licenciada en Veterinaria from the University of Zaragoza in 1989. Her academic inclinations quickly shifted toward molecular genetics, leading her to complete a Ph.D. in Genetics at the same university in 1994. Her early studies were driven by a deep curiosity about the mechanisms of heredity and gene expression, setting the tone for a lifelong commitment to biomedical research. These formative years cultivated her scientific rigor and sowed the seeds for a career that would eventually bridge basic science and translational medicine.

🧬 Professional Endeavors in Genetics and Biomedicine

Prof. Osta currently holds the esteemed title of Catedrática (Full Professor) in the Department of Anatomy, Embryology, and Genetics at the Faculty of Veterinary Medicine, University of Zaragoza. Since 2018, she has led her department with a focus on integrative biomedical sciences. She is the principal investigator of the LAGENBIO group recognized by both the Aragon Health Research Institute and the Government of Aragon. Under her leadership, the group has developed two major subprograms: TERAGEN and REGENERAGEN. As coordinator of the “Neuroscience and Mental Health Program” at IISA, she has spearheaded numerous efforts to understand and address neurological diseases through genetic approaches.

🧠 Contributions and Research Focus in Neuroscience

A prominent figure in neuroscience, Prof. Osta’s research lies at the intersection of genetics and neurodegeneration. She is currently the principal investigator of the only Aragon-based group within CIBERNED (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas), reflecting her national influence. Her team represents Zaragoza in prominent European consortia such as TRICALS and ENCALS, both focused on amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. Through more than 100 indexed publications, predominantly in top-tier journals, her work delves into the molecular underpinnings of neurological disorders and explores regenerative medicine strategies, thereby contributing to innovative therapeutic avenues.

🧪 Accolades and Recognition in Scientific Excellence

Prof. Osta’s academic and research career has been punctuated by consistent recognition. She has completed five research productivity periods and one technology transfer period, acknowledged by CNEAI — a mark of sustained scientific impact. She has led over 74 research projects and contributed to more than 100 collaboration contracts, earning her four competitive research awards from respected institutions including CORIS, AREA, IIS, and SEBBM. Her contributions have been lauded not only for scientific quality but also for practical relevance in biomedical advancements.

🚀 Innovation and Impact in Translational Research

An ardent advocate for science with societal impact, Prof. Osta has significantly contributed to technology transfer. She holds nine patents, five of which have been licensed to industry partners. Her collaborations with companies have led to meaningful translational outputs, emphasizing her role in bridging the gap between academic research and real-world solutions. As former Director of the Technology Transfer and Innovation Secretariat at the University of Zaragoza for nearly a decade, she played a crucial role in institutional innovation strategies. Her involvement in joint university-company chairs and her role in the UZ Technology-Based Business Creation Committee for over 12 years further underscore her influence on academic entrepreneurship.

📚 Mentorship and Educational Leadership

Beyond the lab, Prof. Osta has left a profound mark as an educator and mentor. Since 2013, she has coordinated the Interuniversity Doctoral Program in Biomedical and Biotechnological Sciences, a joint initiative between the Universities of Zaragoza and La Rioja. Her mentorship includes the supervision of 13 Ph.D. theses — 9 of which earned international distinction and 6 received extraordinary doctoral awards. Her influence extends to guiding numerous undergraduate and master’s theses, fostering a new generation of scientists with a deep commitment to research excellence and innovation.

🌍 Legacy and Future Contributions

Prof. Rosario Osta’s legacy is defined by her ability to integrate scientific discovery, mentorship, and innovation. As a member of the Scientific Committee of the Luzón Foundation, her vision reaches beyond academia into public health advocacy and strategic research planning. With nearly 19,000 citations on Google Scholar and an h-index of 45, her work continues to inspire and inform global research communities. Her continued leadership in collaborative European projects ensures her contributions will shape the future of neuroscience, genetics, and translational medicine for years to come.

Publication

Title: Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice
Authors: L. Moreno-Martinez, N. Gaja-Capdevila, L. Mosqueira-Martín, R. Osta, F.J. Gil-Bea
Year: 2025

Title: Identifying Hub Genes and miRNAs Associated with Alzheimer’s Disease: A Bioinformatics Pathway to Novel Therapeutic Strategies
Authors: E. Gascón, A.C. Calvo, N. Molina, P. Zaragoza, R. Osta
Year: 2024

Title: Comparative Blood Profiling Based on ATR-FTIR Spectroscopy and Chemometrics for Differential Diagnosis of Patients with Amyotrophic Lateral Sclerosis—Pilot Study
Authors: K. Tkachenko, J.M. González Sáiz, A.C. Calvo, R. Osta, C. Pizarro Millán
Year: 2024

Title: Sex differences on constitutive long non-coding RNA expression: Modulatory effect of estradiol and testosterone in muscle cells
Authors: T. López-Royo, L. Moreno-Martinez, L. Moreno-García, R. Manzano, R. Osta
Year: 2024

Title: Differentially expressed lncRNAs in SOD1 G93A mice skeletal muscle: H19, Myhas and Neat1 as potential biomarkers in amyotrophic lateral sclerosis
Authors: T. López-Royo, L. Moreno-Martinez, P. Zaragoza, R. Manzano, R. Osta
Year: 2024

Title: Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia
Authors: P. Aparicio, D. Navarrete-Villanueva, A. Gómez-Cabello, R. Osta, R. Manzano
Year: 2024

Title: Sporadic Amyotrophic Lateral Sclerosis Skeletal Muscle Transcriptome Analysis: A Comprehensive Examination of Differentially Expressed Genes
Authors: E. Gascón, P. Zaragoza, A.C. Calvo, R. Osta
Year: 2024

Title: Intermediate Repeat Expansion in the ATXN2 Gene as a Risk Factor in the ALS and FTD Spanish Population
Authors: D. Borrego-Hernández, J.F. Vázquez-Costa, R. Domínguez Rubio, M. Povedano, A. García-Redondo
Year: 2024

Title: New Insights into Endogenous Retrovirus-K Transcripts in Amyotrophic Lateral Sclerosis
Authors: L. Moreno-Martinez, S. Macías-Redondo, M.H.P. Strunk, R. Osta, J. Schoorlemmer
Year: 2024

Title: Analysis of Plasma-Derived Exosomal MicroRNAs as Potential Biomarkers for Canine Idiopathic Epilepsy
Authors: M. García-Gracia, L. Moreno-Martinez, A. Hernaiz, S. García-Belenguer, I. Martín-Burriel
Year: 2024

🏆 Conclusion

Based on her outstanding research contributions, innovation in translational science, mentorship record, and leadership within national and European research programs, Prof. Rosario Osta Pinzolas is an exceptionally strong candidate for the Best Researcher Award. Her profile reflects not only academic excellence but also societal impact and visionary leadership. While there is room for enhanced global outreach, her sustained achievements and contributions make her highly deserving of this prestigious recognition.

Md Shimul Bhuia | Drug development of neurodegenerative disease | Young Scientist Award 

Mr. Md Shimul Bhuia | Drug development of neurodegenerative disease | Young Scientist Award 

Mr. Md Shimul Bhuia , BioLuster Research Center Limited,  Bangladesh.

An accomplished pharmacist and researcher with expertise in pharmaceutical sciences, molecular docking, and drug development. Awarded the prestigious National Science and Technology Fellowship (NST) in 2023 for contributions to science. Extensive experience includes an internship at Beximco Pharmaceuticals, part-time pharmacy practice, and a full-time role as Deputy Director at BioLuster Research Center. Proficient in advanced software for computational drug design and well-versed in research methodologies. Fluent in Bangla and highly proficient in English, with strong technical and analytical skills.

 

profile

scholor

🎓 Education and Academic Achievements

Master of Pharmacy (M. Pharm.) Department of Pharmacy, Life Science Faculty. Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj-8100, Bangladesh Session: 2020–2021 Course Duration: 1.5 years (3 Semesters)Passing Year: 2022 CGPA: 3.74 (out of 4.00). Bachelor of Pharmacy (B. Pharm.) Department of Pharmacy, Life Science Faculty .Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj-8100, BangladeshSession: 2016–2017  Course Duration: 4 years Hon’s (8 Semesters) Passing Year: 2020 CGPA: 3.45 (out of 4.00)  Higher Secondary Certificate (H.S.C.)  Shahid Bul Bul Govt. College, Pabna Board: Rajshahi Group: Science Passing Year: 2016 GPA: 5.00 (out of 5.00) Secondary School Certificate (S.S.C.) Kamal Pur T.M. High School, Ishwardi, Pabna Board: Rajshahi  Group: Science Passing Year: 2013 GPA: 5.00 (out of 5.00).

🎯 Research Interests

Neurology/Neurodegenerative Diseases , Immunology ,  Cancer Therapy , Toxicology , Molecular Docking , Drug Design and Development via Computational Studies ,Pharmacological Investigation through Preclinical Test Systems , Inflammatory Diseases , Bioinformatics , Anti-cancer Agents

🏆 Honours and Awards

National Science and Technology Fellowship (NST), 2023. Awarded by the Ministry of Science and Technology, Government of Bangladesh

💼 Work Experiences

InternshipBeximco Pharmaceutical Ltd., Squibb Road, Tongi, Bangladesh Duration: November 13, 2022, to November 23, 2022. Pharmacist Worked as a pharmacist at Gafur Chikitsaloi (local pharmacy shop)Employee Status: Part-Researcher Deputy Director, BioLuster Research Center, Gopalganj 8100, Dhaka, Bangladesh Employee Status: Full-time (January 01 – Present)

📚 Publications

 

 Conclusion

With a strong foundation in both clinical practice and academic leadership, Leila Sadati’s career reflects a commitment to advancing healthcare education and patient safety standards. Her contributions in research, curriculum development, and operational management have shaped future medical professionals and enhanced patient care practices. As she continues to innovate and educate, her work remains instrumental in raising the standards of medical and surgical education in Iran and beyond.